Please ensure Javascript is enabled for purposes of website accessibility

Why ChemoCentryx Stock Skyrocketed Today

By Joe Tenebruso – Oct 8, 2021 at 5:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are excited about the biotech's game-changing new drug.

What happened

Shares of ChemoCentryx (CCXI) soared 96% on Friday after the biopharmaceutical company received Food and Drug Administration approval for its treatment for a rare autoimmune disease.  

So what

ChemoCentryx's orally administered drug, avacopan, will be sold under the brand name Tavneos. It's designed to help treat ANCA-associated vasculitis, a condition in which an overreaction in the immune system leads to inflammation and destruction of small blood vessels that can result in fatal organ failure.

"Today is a momentous day in the history of ChemoCentryx; the culmination of decades of effort aimed at offering new hope to patients with this and other debilitating and deadly diseases," CEO Thomas Schall said in a press release.

A person is pointing to an upwardly sloping line.

ChemoCentryx's stock price nearly doubled on Friday. Image source: Getty Images.

Patients and investors alike cheered the news. "There is a significant unmet need in the treatment of ANCA-associated vasculitis, with current therapies often leading to serious, even fatal, side effects and a diminished quality of life,"  the Vasculitis Foundation's executive director, Joyce Kullman, said. "We believe new therapies like Tavneos may offer a brighter future for these patients."

Now what

ChemoCentryx owns the commercial rights to Tavneos in the U.S., where roughly 9,500 people are expected to be diagnosed with severe forms of ANCA-associated vasculitis. The drug will sell for a wholesale price of as much as $200,000 annually. 

Analysts, in turn, estimate that ChemoCentryx could generate revenue of $1.3 billion from sales of Tavneos by 2035. A windfall of that magnitude could be huge for the company, which has recorded only $21.2 million in revenue over the past year. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

ChemoCentryx Stock Quote
ChemoCentryx
CCXI

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.